• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 10-Q filed by Innospec Inc.

    5/9/25 9:46:52 AM ET
    $IOSP
    Major Chemicals
    Industrials
    Get the next $IOSP alert in real time by email
    10-Q
    Q1false--12-310001054905DEhttp://innospec.com/20250331#PresidentAndChiefExecutiveOfficerMember0001054905us-gaap:ResearchAndDevelopmentExpenseMember2025-01-012025-03-310001054905us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001054905us-gaap:AdditionalPaidInCapitalMember2023-12-310001054905us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001054905us-gaap:NoncontrollingInterestMember2024-12-310001054905us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001054905us-gaap:CarryingReportedAmountFairValueDisclosureMemberiosp:EmissionTradingSchemeCreditsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001054905us-gaap:AdditionalPaidInCapitalMember2024-12-310001054905us-gaap:RetainedEarningsMember2025-01-012025-03-310001054905iosp:PerformanceChemicalsMember2025-01-012025-03-310001054905us-gaap:TreasuryStockCommonMember2024-12-310001054905us-gaap:CommonStockMember2024-03-310001054905us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-03-310001054905us-gaap:RetainedEarningsMember2024-01-012024-03-310001054905iosp:PersonalCareMemberus-gaap:OperatingSegmentsMemberiosp:PerformanceChemicalsMember2024-01-012024-03-310001054905iosp:AdvanSixMember2024-12-3100010549052025-01-010001054905us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001054905iosp:OtherNetIncomeExpenseMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2025-01-012025-03-310001054905us-gaap:OperatingSegmentsMemberiosp:FuelSpecialtiesMember2025-01-012025-03-310001054905us-gaap:CarryingReportedAmountFairValueDisclosureMemberiosp:EmissionTradingSchemeCreditsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001054905us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-03-310001054905us-gaap:RevolvingCreditFacilityMember2025-01-012025-03-310001054905us-gaap:CommonStockMember2024-12-310001054905us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001054905us-gaap:OperatingSegmentsMemberiosp:OilfieldServicesMember2024-01-012024-03-3100010549052024-03-310001054905us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001054905us-gaap:TreasuryStockCommonMember2025-03-310001054905us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2025-03-310001054905us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001054905us-gaap:CommonStockMember2023-12-310001054905us-gaap:CorporateNonSegmentMember2025-01-012025-03-310001054905us-gaap:AdditionalPaidInCapitalMember2024-03-310001054905us-gaap:OperatingSegmentsMember2024-01-012024-03-310001054905us-gaap:OperatingSegmentsMemberiosp:PerformanceChemicalsMember2025-01-012025-03-310001054905us-gaap:OperatingSegmentsMemberiosp:FuelSpecialtiesMemberiosp:RefineryAndPerformanceMember2024-01-012024-03-3100010549052025-04-300001054905us-gaap:CommonStockMember2025-03-310001054905us-gaap:NoncontrollingInterestMember2025-03-310001054905us-gaap:NoncontrollingInterestMember2024-01-012024-03-310001054905us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001054905srt:EuropeMember2024-12-310001054905us-gaap:OperatingSegmentsMemberiosp:FuelSpecialtiesMemberiosp:OtherFuelSpecialtiesMember2025-01-012025-03-310001054905us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-03-310001054905us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2025-03-310001054905us-gaap:TreasuryStockCommonMember2024-03-310001054905us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001054905iosp:StockEquivalentUnitsMember2024-01-012024-03-310001054905us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001054905us-gaap:RevolvingCreditFacilityMember2024-01-012024-03-3100010549052025-03-310001054905iosp:EuropeanMetalRecyclingLimitedMember2025-03-310001054905us-gaap:FairValueInputsLevel3Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2025-03-310001054905us-gaap:TreasuryStockCommonMember2023-12-310001054905us-gaap:RetainedEarningsMember2025-03-310001054905iosp:GermanPlanMembercountry:DE2024-01-012024-03-310001054905iosp:RemediationMember2024-01-012024-03-310001054905srt:EuropeMember2025-03-310001054905us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-01-012024-03-310001054905iosp:UkPlanMember2025-03-310001054905iosp:AdvanSixMember2024-01-012024-03-3100010549052023-12-310001054905us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-01-012025-03-310001054905us-gaap:NoncontrollingInterestMember2025-01-012025-03-310001054905us-gaap:RevolvingCreditFacilityMember2025-03-310001054905us-gaap:SoftwareDevelopmentMember2025-01-012025-03-310001054905iosp:SmithGambrellAndRussellLimitedLiabilityPartnershipMember2024-03-310001054905us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-12-310001054905us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-03-310001054905iosp:AdvanSixMember2025-01-012025-03-310001054905us-gaap:OperatingSegmentsMemberiosp:HomeCareMemberiosp:PerformanceChemicalsMember2024-01-012024-03-310001054905us-gaap:FairValueInputsLevel3Memberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:FairValueMeasurementsRecurringMember2024-12-310001054905us-gaap:RetainedEarningsMember2023-12-310001054905iosp:PersonalCareMemberus-gaap:OperatingSegmentsMemberiosp:PerformanceChemicalsMember2025-01-012025-03-310001054905us-gaap:OperatingSegmentsMemberiosp:PerformanceChemicalsMember2024-01-012024-03-310001054905iosp:EmissionTradingSchemeCreditsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-12-310001054905iosp:GermanPlanMembercountry:DE2025-01-012025-03-310001054905us-gaap:RevolvingCreditFacilityMember2024-12-310001054905iosp:AdvanSixMember2025-03-310001054905us-gaap:NoncontrollingInterestMember2023-12-310001054905srt:MaximumMember2025-01-012025-03-310001054905us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-3100010549052024-01-012024-03-310001054905us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-01-012025-03-310001054905us-gaap:NoncontrollingInterestMember2024-03-310001054905srt:MaximumMemberiosp:EuropeanMetalRecyclingLimitedMember2024-01-012024-03-310001054905us-gaap:OperatingSegmentsMember2025-01-012025-03-310001054905us-gaap:OperatingSegmentsMemberiosp:FuelSpecialtiesMemberiosp:OtherFuelSpecialtiesMember2024-01-012024-03-310001054905us-gaap:EmployeeStockOptionMember2024-01-012024-03-310001054905iosp:EuropeanMetalRecyclingLimitedMember2024-12-310001054905us-gaap:RetainedEarningsMember2024-12-310001054905us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310001054905srt:MaximumMemberiosp:EuropeanMetalRecyclingLimitedMember2025-01-012025-03-3100010549052025-01-012025-03-310001054905us-gaap:OperatingSegmentsMemberiosp:FuelSpecialtiesMember2024-01-012024-03-310001054905us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001054905us-gaap:RetainedEarningsMember2024-03-310001054905us-gaap:OperatingSegmentsMemberiosp:FuelSpecialtiesMemberiosp:RefineryAndPerformanceMember2025-01-012025-03-310001054905us-gaap:AccumulatedTranslationAdjustmentMember2025-03-310001054905us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001054905us-gaap:TreasuryStockCommonMember2025-01-012025-03-310001054905iosp:EmissionTradingSchemeCreditsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2025-03-310001054905us-gaap:AccumulatedTranslationAdjustmentMember2024-03-3100010549052024-12-310001054905us-gaap:OperatingSegmentsMemberiosp:OilfieldServicesMember2025-01-012025-03-310001054905us-gaap:CorporateNonSegmentMember2024-01-012024-03-310001054905us-gaap:AccumulatedTranslationAdjustmentMember2024-12-310001054905iosp:OtherPerformanceChemicalsMemberus-gaap:OperatingSegmentsMemberiosp:PerformanceChemicalsMember2025-01-012025-03-310001054905us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-310001054905us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310001054905us-gaap:AccumulatedTranslationAdjustmentMember2025-01-012025-03-310001054905iosp:RemediationMember2025-01-012025-03-310001054905us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-12-310001054905us-gaap:AdditionalPaidInCapitalMember2025-03-310001054905iosp:OtherNetIncomeExpenseMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2024-01-012024-03-310001054905iosp:StockEquivalentUnitsMember2025-01-012025-03-310001054905iosp:OtherPerformanceChemicalsMemberus-gaap:OperatingSegmentsMemberiosp:PerformanceChemicalsMember2024-01-012024-03-310001054905us-gaap:OperatingSegmentsMemberiosp:HomeCareMemberiosp:PerformanceChemicalsMember2025-01-012025-03-310001054905us-gaap:TreasuryStockCommonMember2024-01-012024-03-310001054905us-gaap:PensionPlansDefinedBenefitMemberiosp:UkPlanMember2025-03-310001054905us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-12-31xbrli:pureiso4217:USDxbrli:sharesxbrli:sharesiosp:Segmentiso4217:USD

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 10-Q

    ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the quarterly period ended March 31, 2025

    or

    ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    For the transition period from to

    Commission file number 1-13879

    INNOSPEC INC.

    (Exact name of registrant as specified in its charter)

     

     

    DELAWARE

     

    98-0181725

     

     

    (State or other jurisdiction of incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

     

     

     

     

     

     

    8310 South Valley Highway Suite 350

    Englewood

     

     

     

     

     

     

     

     

     

    Colorado

     

    80112

     

     

    (Address of principal executive offices)

     

    (Zip Code)

     

     

    Registrant’s telephone number, including area code: (303) 792 5554

     

    Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common stock, par value $0.01 per share

     

    IOSP

     

    NASDAQ

     

    Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

    Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such file. Yes ☒ No ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☒

    Accelerated filer

    ☐

    Non-accelerated filer

    ☐

    Smaller reporting company

    ☐

    Emerging growth company

    ☐

     

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

    Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

     

     

    Class

     

    Outstanding as of April 30, 2025

     

     

    Common Stock, par value $0.01

     

    24,959,999

     

     

     


     

    TABLE OF CONTENTS

     

     

     

    PART I

    FINANCIAL INFORMATION

    2

    Item 1

    Condensed Consolidated Financial Statements

    2

     

    Condensed Consolidated Statements of Income

    2

     

    Condensed Consolidated Statements of Comprehensive Income

    3

     

    Condensed Consolidated Balance Sheets

    4

     

    Condensed Consolidated Statements of Cash Flows

    5

     

    Condensed Consolidated Statements of Equity

    6

     

    Notes To The Unaudited Interim Condensed Consolidated Financial Statements

    7

    Item 2

    Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three Months Ended March 31, 2025

    17

     

    Critical Accounting Estimates

    17

     

    Results of Operations

    17

     

    Liquidity and Financial Condition

    21

    Item 3

    Quantitative and Qualitative Disclosures about Market Risk

    23

    Item 4

    Controls and Procedures

    24

    PART II

    OTHER INFORMATION

    25

    Item 1

    Legal Proceedings

    25

    Item 1A

    Risk Factors

    25

    Item 2

    Unregistered Sales of Equity Securities and Use of Proceeds

    25

    Item 3

    Defaults Upon Senior Securities

    25

    Item 4

    Mine Safety Disclosures

    25

    Item 5

    Other Information

    25

    Item 6

    Exhibits

    26

     

    SIGNATURES

     

    27

     

     


     

    CAUTIONARY STATEMENT RELATIVE TO FORWARD-LOOKING STATEMENTS

    This Form 10-Q contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included or incorporated herein may constitute forward-looking statements. Such forward-looking statements include statements (covered by words like “expects,” “estimates,” “anticipates,” “may,” “could,” “believes,” “feels,” “plans,” “intends,” “outlook” or similar words or expressions, for example) which relate to earnings, growth potential, operating performance, events or developments that we expect or anticipate will or may occur in the future. Although forward-looking statements are believed by management to be reasonable when made, they are subject to certain risks, uncertainties and assumptions, and our actual performance or results may differ materially from these forward-looking statements. Additional information regarding risks, uncertainties and assumptions relating to Innospec and affecting our business operations and prospects are described in Innospec’s Annual Report on Form 10-K for the year ended December 31, 2024, and other reports filed with the U.S. Securities and Exchange Commission ("SEC"). You are urged to review our discussion of risks and uncertainties that could cause actual results to differ from forward-looking statements under the heading “Risk Factors” in such reports. Innospec undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    1


     

    PART I FINANCIAL INFORMATION

    Item 1 Condensed Consolidated Financial Statements

    INNOSPEC INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF INCOME

    (Unaudited)

     

     

    Three Months Ended
    March 31,

     

    (in millions, except share and per share data)

     

    2025

     

     

    2024

     

    Net sales

     

    $

    440.8

     

     

    $

    500.2

     

    Cost of goods sold

     

     

    (315.7

    )

     

     

    (344.5

    )

    Gross profit

     

     

    125.1

     

     

     

    155.7

     

    Operating expenses:

     

     

     

     

     

     

    Selling, general and administrative

     

     

    (69.3

    )

     

     

    (90.5

    )

    Research and development

     

     

    (12.7

    )

     

     

    (14.0

    )

    Adjustment to fair value of contingent consideration

     

     

    (0.7

    )

     

     

    (0.8

    )

    Profit on disposal of property, plant and equipment

     

     

    0.1

     

     

     

    0.1

     

    Total operating expenses

     

     

    (82.6

    )

     

     

    (105.2

    )

    Operating income

     

     

    42.5

     

     

     

    50.5

     

    Other income/(expense), net

     

     

    (0.5

    )

     

     

    2.7

     

    Interest income, net

     

     

    2.4

     

     

     

    2.1

     

    Income before income tax expense

     

     

    44.4

     

     

     

    55.3

     

    Income tax expense

     

     

    (11.6

    )

     

     

    (13.9

    )

    Net income

     

    $

    32.8

     

     

    $

    41.4

     

    Earnings per share:

     

     

     

     

     

     

    Basic

     

    $

    1.31

     

     

    $

    1.66

     

    Diluted

     

    $

    1.31

     

     

    $

    1.65

     

    Weighted average shares outstanding (in thousands):

     

     

     

     

     

     

    Basic

     

     

    24,970

     

     

     

    24,893

     

    Diluted

     

     

    25,102

     

     

     

    25,066

     

     

    The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

    2


     

    INNOSPEC INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

    (Unaudited)

     

     

    Three Months Ended
    March 31,

     

    (in millions)

     

    2025

     

     

    2024

     

    Net income

     

    $

    32.8

     

     

    $

    41.4

     

    Other comprehensive income/(loss):

     

     

     

     

     

     

       Changes in cumulative translation adjustment

     

     

    18.4

     

     

     

    (7.7

    )

       Amortization of prior service cost

     

     

    —

     

     

     

    0.1

     

       Amortization of actuarial net gains

     

     

    —

     

     

     

    (0.1

    )

    Other comprehensive income/(loss), before tax

     

     

    18.4

     

     

     

    (7.7

    )

       Tax related to cumulative translation adjustment

     

     

    0.3

     

     

     

    0.4

     

       Tax related to other movements

     

     

    —

     

     

     

    —

     

    Income tax income/(expense) related to other comprehensive income

     

     

    0.3

     

     

     

    0.4

     

    Total comprehensive income

     

    $

    51.5

     

     

    $

    34.1

     

     

     

    The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

    3


     

    INNOSPEC INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (Unaudited)

    (in millions, except share and per share data)

     

    March 31,
    2025

     

     

    December 31,
    2024

     

    Assets

     

     

     

     

     

     

    Current assets:

     

     

     

     

     

     

    Cash and cash equivalents

     

    $

    299.8

     

     

    $

    289.2

     

    Trade and other accounts receivable (less allowances of $9.6 million and $11.9 million
       respectively)

     

     

    343.5

     

     

     

    341.7

     

    Inventories (less allowances of $35.8 million and $34.6 million respectively):

     

     

     

     

     

     

    Finished goods

     

     

    216.4

     

     

     

    197.9

     

    Raw materials

     

     

    99.0

     

     

     

    103.1

     

    Total inventories

     

     

    315.4

     

     

     

    301.0

     

    Prepaid expenses

     

     

    16.0

     

     

     

    21.0

     

    Prepaid income taxes

     

     

    1.0

     

     

     

    3.1

     

    Other current assets

     

     

    1.4

     

     

     

    0.6

     

    Total current assets

     

     

    977.1

     

     

     

    956.6

     

    Net property, plant and equipment

     

     

    277.1

     

     

     

    269.7

     

    Operating lease right-of-use assets

     

     

    44.4

     

     

     

    44.8

     

    Goodwill

     

     

    388.4

     

     

     

    382.5

     

    Other intangible assets

     

     

    72.8

     

     

     

    65.4

     

    Deferred tax assets

     

     

    8.6

     

     

     

    9.4

     

    Pension asset

     

     

    1.2

     

     

     

    2.4

     

    Other non-current assets

     

     

    5.0

     

     

     

    3.9

     

    Total assets

     

    $

    1,774.6

     

     

    $

    1,734.7

     

     

    Liabilities and Equity

     

     

     

     

     

     

    Current liabilities:

     

     

     

     

     

     

    Accounts payable

     

    $

    169.5

     

     

    $

    163.8

     

    Accrued liabilities

     

     

    147.5

     

     

     

    169.1

     

    Current portion of operating lease liabilities

     

     

    14.0

     

     

     

    13.9

     

    Current portion of plant closure provisions

     

     

    5.0

     

     

     

    5.0

     

    Accrued income taxes

     

     

    21.6

     

     

     

    19.6

     

    Total current liabilities

     

     

    357.6

     

     

     

    371.4

     

    Operating lease liabilities, net of current portion

     

     

    30.4

     

     

     

    31.0

     

    Plant closure provisions, net of current portion

     

     

    57.2

     

     

     

    55.3

     

    Deferred tax liabilities

     

     

    23.0

     

     

     

    23.5

     

    Pension liabilities and post-employment benefits

     

     

    12.9

     

     

     

    13.1

     

    Acquisition-related contingent consideration

     

     

    22.6

     

     

     

    20.1

     

    Other non-current liabilities

     

     

    5.2

     

     

     

    4.2

     

    Total liabilities

     

     

    508.9

     

     

     

    518.6

     

    Equity:

     

     

     

     

     

     

    Common stock, $0.01 par value, authorized 40,000,000 shares, issued 29,554,500
       shares

     

     

    0.3

     

     

     

    0.3

     

    Additional paid-in capital

     

     

    370.7

     

     

     

    369.9

     

    Treasury stock (4,580,264 and 4,594,943 shares at cost, respectively)

     

     

    (96.5

    )

     

     

    (93.0

    )

    Retained earnings

     

     

    1,057.8

     

     

     

    1,025.0

     

    Accumulated other comprehensive loss

     

     

    (72.3

    )

     

     

    (91.0

    )

    Total Innospec stockholders’ equity

     

     

    1,260.0

     

     

     

    1,211.2

     

    Non-controlling interest

     

     

    5.7

     

     

     

    4.9

     

    Total equity

     

     

    1,265.7

     

     

     

    1,216.1

     

    Total liabilities and equity

     

    $

    1,774.6

     

     

    $

    1,734.7

     

     

    The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

    4


     

    INNOSPEC INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (Unaudited)

     

     

    Three Months Ended
    March 31,

     

    (in millions)

     

    2025

     

     

    2024

     

    Cash Flows from Operating Activities

     

     

     

     

     

     

    Net income

     

    $

    32.8

     

     

    $

    41.4

     

    Adjustments to reconcile net income to net cash provided by operating activities:

     

     

     

     

     

     

    Depreciation and amortization

     

     

    10.9

     

     

     

    10.4

     

    Adjustment to fair value of contingent consideration

     

     

    0.7

     

     

     

    0.8

     

    Deferred taxes

     

     

    (0.3

    )

     

     

    0.8

     

    Profit on disposal of property, plant and equipment

     

     

    (0.1

    )

     

     

    (0.1

    )

    Non-cash movements on defined benefit pension plans

     

     

    1.3

     

     

     

    (0.8

    )

    Stock option compensation

     

     

    1.9

     

     

     

    2.1

     

    Changes in assets and liabilities, net of effects of acquired and divested companies:

     

     

     

     

     

     

    Trade and other accounts receivable

     

     

    6.6

     

     

     

    39.5

     

    Inventories

     

     

    (6.6

    )

     

     

    (6.0

    )

    Prepaid expenses

     

     

    5.4

     

     

     

    3.6

     

    Accounts payable and accrued liabilities

     

     

    (27.0

    )

     

     

    (19.7

    )

    Plant closure provisions

     

     

    (0.4

    )

     

     

    (0.1

    )

    Income taxes

     

     

    4.3

     

     

     

    8.8

     

    Unrecognized tax benefits

     

     

    —

     

     

     

    0.2

     

    Other assets and liabilities

     

     

    (1.2

    )

     

     

    (0.3

    )

    Net cash provided by operating activities

     

     

    28.3

     

     

     

    80.6

     

    Cash Flows from Investing Activities

     

     

     

     

     

     

    Capital expenditures

     

     

    (8.4

    )

     

     

    (10.7

    )

    Internally developed software

     

     

    (7.2

    )

     

     

    (3.7

    )

    Proceeds on disposal of property, plant and equipment

     

     

    0.1

     

     

     

    0.1

     

    Net cash used in investing activities

     

     

    (15.5

    )

     

     

    (14.3

    )

    Cash Flows from Financing Activities

     

     

     

     

     

     

    Non-controlling interest

     

     

    0.8

     

     

     

    0.2

     

    Issue of treasury stock

     

     

    0.2

     

     

     

    0.7

     

    Repurchase of common stock

     

     

    (4.8

    )

     

     

    (0.4

    )

    Net cash provided by/(used in) financing activities

     

     

    (3.8

    )

     

     

    0.5

     

    Effect of foreign currency exchange rate changes on cash

     

     

    1.6

     

     

     

    (0.4

    )

    Net change in cash and cash equivalents

     

     

    10.6

     

     

     

    66.4

     

    Cash and cash equivalents at beginning of period

     

     

    289.2

     

     

     

    203.7

     

    Cash and cash equivalents at end of period

     

    $

    299.8

     

     

    $

    270.1

     

     

    The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

    5


     

    INNOSPEC INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

    (Unaudited)

     

    (in millions)

     

    Common
    Stock

     

     

    Additional
    Paid-In
    Capital

     

     

    Treasury
    Stock

     

     

    Retained
    Earnings

     

     

    Accumulated
    Other
    Comprehensive
    Loss

     

     

    Non-
    Controlling
    Interest

     

     

    Total
    Equity

     

    Balance at December 31, 2024

     

    $

    0.3

     

     

    $

    369.9

     

     

    $

    (93.0

    )

     

    $

    1,025.0

     

     

    $

    (91.0

    )

     

    $

    4.9

     

     

    $

    1,216.1

     

    Net income

     

     

     

     

     

     

     

     

     

     

     

    32.8

     

     

     

     

     

     

     

     

     

    32.8

     

    Changes in cumulative translation adjustment,
       net of tax

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    18.7

     

     

     

     

     

     

    18.7

     

    Share of net income

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    0.8

     

     

     

    0.8

     

    Treasury stock reissued

     

     

     

     

     

    (1.1

    )

     

     

    1.3

     

     

     

     

     

     

     

     

     

     

     

     

    0.2

     

    Treasury stock repurchased

     

     

     

     

     

     

     

     

    (4.8

    )

     

     

     

     

     

     

     

     

     

     

     

    (4.8

    )

    Stock option compensation

     

     

     

     

     

    1.9

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    1.9

     

    Amortization of prior service cost, net of tax

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    —

     

     

     

     

     

     

    —

     

    Amortization of actuarial net gains, net of tax

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    —

     

     

     

     

     

     

    —

     

    Balance at March 31, 2025

     

    $

    0.3

     

     

    $

    370.7

     

     

    $

    (96.5

    )

     

    $

    1,057.8

     

     

    $

    (72.3

    )

     

    $

    5.7

     

     

    $

    1,265.7

     

     

    (in millions)

     

    Common
    Stock

     

     

    Additional
    Paid-In
    Capital

     

     

    Treasury
    Stock

     

     

    Retained
    Earnings

     

     

    Accumulated
    Other
    Comprehensive
    Loss

     

     

    Non-
    Controlling
    Interest

     

     

    Total
    Equity

     

    Balance at December 31, 2023

     

    $

    0.3

     

     

    $

    361.0

     

     

    $

    (94.3

    )

     

    $

    1,028.2

     

     

    $

    (148.1

    )

     

    $

    2.5

     

     

    $

    1,149.6

     

    Net income

     

     

     

     

     

     

     

     

     

     

     

    41.4

     

     

     

     

     

     

     

     

     

    41.4

     

    Changes in cumulative translation adjustment, net of tax

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    (7.3

    )

     

     

     

     

     

    (7.3

    )

    Share of net income

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    0.1

     

     

     

    0.1

     

    Treasury stock reissued

     

     

     

     

     

    (0.7

    )

     

     

    1.4

     

     

     

     

     

     

     

     

     

     

     

     

    0.7

     

    Treasury stock repurchased

     

     

     

     

     

     

     

     

    (0.4

    )

     

     

     

     

     

     

     

     

     

     

     

    (0.4

    )

    Stock option compensation

     

     

     

     

     

    2.1

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    2.1

     

    Amortization of prior service cost, net of tax

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    0.1

     

     

     

     

     

     

    0.1

     

    Amortization of actuarial net losses, net of tax

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    (0.1

    )

     

     

     

     

     

    (0.1

    )

    Balance at March 31, 2024

     

    $

    0.3

     

     

    $

    362.4

     

     

    $

    (93.3

    )

     

    $

    1,069.6

     

     

    $

    (155.4

    )

     

    $

    2.6

     

     

    $

    1,186.2

     

     

    The accompanying notes are an integral part of these unaudited interim condensed consolidated financial statements.

     

     

    6


     

    INNOSPEC INC. AND SUBSIDIARIES

    NOTES TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

    NOTE 1 – BASIS OF PRESENTATION

    The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934. Accordingly, they do not include all the information and notes necessary for a comprehensive presentation of financial position, results of operations and cash flows.

    During the year, the Company has reclassified prior period amounts to conform to the 2025 presentation. The reclassification had no impact on previously reported total net revenue, operating income or net income. For the first quarter of 2025, this has resulted in $1.9 million (first quarter of 2024 - $2.2 million) of costs that were previously disclosed within selling, general and administrative expenses, being moved to research and development expenses.

    It is our opinion, however, that all adjustments (consisting of normal, recurring adjustments, unless otherwise disclosed) have been made which are necessary for the condensed consolidated financial statements to be fairly stated. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed on February 19, 2025 (the “2024 Form 10-K”).

    The results for the interim period covered by this report are not necessarily indicative of the results to be expected for the full year.

    When we use the terms “Innospec,” “the Corporation,” “the Company,” “Registrant,” “the Group,” “we,” “us” and “our,” we are referring to Innospec Inc. and its consolidated subsidiaries unless otherwise indicated or the context otherwise requires.

    NOTE 2 – SEGMENT REPORTING

    The Company reports its financial performance based on three reportable segments, which are Performance Chemicals, Fuel Specialties and Oilfield Services.

    The Chief Operating Decision Maker (“CODM”) is the President and Chief Executive Officer (the Principal Executive Officer) and is a Director of Innospec Inc.. The CODM evaluates the performance of the Company’s segments and makes strategic decisions relating to the Company's allocation of resources, based on the segments' gross profit and operating income.

    7


     

    The following table analyzes sales and other financial information by the Company’s reportable segments:

     

     

    Three Months Ended
    March 31,

     

    (in millions)

     

    2025

     

     

    2024

     

    Net Sales:

     

     

     

     

     

     

    Personal Care

     

    $

    100.6

     

     

    $

    94.8

     

    Home Care

     

     

    26.3

     

     

     

    26.4

     

    Other

     

     

    41.5

     

     

     

    39.6

     

    Performance Chemicals

     

     

    168.4

     

     

     

    160.8

     

    Refinery and Performance

     

     

    129.4

     

     

     

    145.1

     

    Other

     

     

    40.9

     

     

     

    31.8

     

    Fuel Specialties

     

     

    170.3

     

     

     

    176.9

     

    Oilfield Services

     

     

    102.1

     

     

     

    162.5

     

     

    $

    440.8

     

     

    $

    500.2

     

    Gross profit:

     

     

     

     

     

     

    Performance Chemicals

     

    $

    35.3

     

     

    $

    37.7

     

    Fuel Specialties

     

     

    60.8

     

     

     

    60.6

     

    Oilfield Services

     

     

    29.0

     

     

     

    57.4

     

    Total gross profit

     

    $

    125.1

     

     

    $

    155.7

     

    Operating income/(loss):

     

     

     

     

     

     

    Performance Chemicals

     

    $

    19.8

     

     

    $

    21.1

     

    Fuel Specialties

     

     

    36.9

     

     

     

    33.4

     

    Oilfield Services

     

     

    4.1

     

     

     

    16.9

     

    Corporate costs

     

     

    (17.7

    )

     

     

    (20.2

    )

    Adjustment to fair value of contingent consideration

     

     

    (0.7

    )

     

     

    (0.8

    )

    Profit on disposal of property, plant and equipment

     

     

    0.1

     

     

     

    0.1

     

    Total operating income

     

    $

    42.5

     

     

    $

    50.5

     

     

    The difference between net sales and gross profit is defined as cost of goods sold. The difference between segmental gross profit and operating income/(expense) is split between selling, general and administrative expenses and research and development expenses.

     


    The following table analyzes cost of goods sold by the Company’s reportable segments:

     

    (in millions)

     

    2025

     

     

    2024

     

    Performance Chemicals

     

    $

    133.1

     

     

    $

    123.1

     

    Fuel Specialties

     

     

    109.5

     

     

     

    116.3

     

    Oilfield Services

     

     

    73.1

     

     

     

    105.1

     

    Total cost of goods sold

     

    $

    315.7

     

     

    $

    344.5

     

     

    The following table analyzes selling, general and administrative expenses and research and development expenses by the Company’s reportable segments:

     

    (in millions)

     

    2025

     

     

    2024

     

    Performance Chemicals

     

    $

    15.5

     

     

    $

    16.6

     

    Fuel Specialties

     

     

    23.9

     

     

     

    27.2

     

    Oilfield Services

     

     

    24.9

     

     

     

    40.5

     

    Corporate

     

     

    17.7

     

     

     

    20.2

     

    Total selling, general and administrative expenses and research and development expenses

     

    $

    82.0

     

     

    $

    104.5

     

     

    8


     

    NOTE 3 – EARNINGS PER SHARE

    Basic earnings per share is based on the weighted average number of common shares outstanding during the period. Diluted earnings per share includes the effect of options that are dilutive and outstanding during the period under the treasury stock method. Per share amounts are computed as follows:

     

     

    Three Months Ended
    March 31,

     

     

    2025

     

     

    2024

     

    Numerator (in millions):

     

     

     

     

     

     

    Net income available to common stockholders

     

    $

    32.8

     

     

    $

    41.4

     

    Denominator (in thousands):

     

     

     

     

     

     

    Weighted average common shares outstanding

     

     

    24,970

     

     

     

    24,893

     

    Dilutive effect of stock options and awards

     

     

    132

     

     

     

    173

     

    Denominator for diluted earnings per share

     

     

    25,102

     

     

     

    25,066

     

    Net income per share, basic:

     

    $

    1.31

     

     

    $

    1.66

     

    Net income per share, diluted:

     

    $

    1.31

     

     

    $

    1.65

     

     

    In the three months ended March 31, 2025, the average number of anti-dilutive options excluded from the calculation of diluted earnings per share were 10,342 (three months ended March 31, 2024 – 31,184).

    NOTE 4 – GOODWILL

    The following table summarizes the goodwill movements in the year:

     

    (in millions)

     

    2025

     

    Opening balance at January 1,

     

    $

    382.5

     

    Exchange effect

     

     

    5.9

     

    Closing balance at March 31

     

    $

    388.4

     

     

    The exchange effect for the three months ended March 31, 2025 was $5.9 million relating to our Performance Chemicals segment.

     

     

    NOTE 5 – OTHER INTANGIBLE ASSETS

    The following table analyzes other intangible assets movements in the year:

     

    (in millions)

     

    2025

     

    Gross cost at January 1

     

    $

    331.8

     

    Additions

     

     

    7.2

     

    Exchange effect

     

     

    5.7

     

    Gross cost at March 31

     

     

    344.7

     

    Accumulated amortization at January 1

     

     

    (266.4

    )

    Amortization expense

     

     

    (2.7

    )

    Exchange effect

     

     

    (2.8

    )

    Accumulated amortization at March 31

     

     

    (271.9

    )

    Net book amount at March 31

     

    $

    72.8

     

     

    The amortization expense for the three months ended March 31, 2025 was $2.7 million (three months ended March 31, 2024 – $2.8 million).

     

    9


     

    In 2025, we have capitalized $7.2 million in relation to our internally developed software for a new Enterprise Resource Planning (“ERP”) system covering all our regions. The project is ongoing and is currently expected to complete in 2026. The expenses capitalized include the acquisition costs for the software as well as the external consultancy costs and the internal employee costs relating to the software development.

     

    NOTE 6 – PENSION AND POST EMPLOYMENT BENEFITS

    The Company previously maintained a defined benefit pension plan covering certain current and former employees in the United Kingdom (the “UK Plan”).

    The UK Plan was bought out in the fourth quarter of 2024, therefore the company is no longer responsible for the future obligation for retirement benefits due to current and former employees. The remaining asset on the balance sheet of $1.3 million relates to cash held to cover the remaining expenses of the scheme and a negligible remaining Projected Benefit Obligation ("PBO") of $0.1 million, reflecting the UK Plan’s residual liabilities in respect of Guaranteed Minimum Pension equalization top-up payments due to former members of the UK Plan. Following the UK Plan buy-out, the Company is no longer required to make future cash contributions to the UK Plan. We expect the UK Plan to be fully wound up during 2025.

    The Company also maintains an unfunded defined benefit pension plan covering certain current and former employees in Germany (the “German plan”). The German plan is closed to new entrants and has no assets. As at March 31, 2025, we have recorded a liability of $9.3 million (December 31, 2024 – $9.0 million).

     

    The net periodic benefit of these plans is shown in the following table:

     

     

    Three Months Ended
    March 31,

     

    (in millions)

     

    2025

     

     

    2024

     

    Service credit/(cost)

     

    $

    (1.2

    )

     

    $

    (0.8

    )

    Interest cost on projected benefit obligation

     

     

    (0.1

    )

     

     

    (4.7

    )

    Expected return on plan assets

     

     

    —

     

     

     

    6.4

     

    Amortization of prior service cost

     

     

    —

     

     

     

    (0.1

    )

    Amortization of actuarial net gains

     

     

    —

     

     

     

    0.1

     

    Net periodic benefit

     

    $

    (1.3

    )

     

    $

    0.9

     

     

    The service cost has been recognized in selling, general and administrative expenses. All other items have been recognized within other income and expense. The amortization of prior service cost and actuarial net gains are a reclassification out of accumulated other comprehensive loss into other income and expense.

    In addition, we have obligations for post-employment benefits in some of our other European businesses. As at March 31, 2025, we have recorded a liability of $3.6 million (December 31, 2024 – $4.1 million).

    10


     

    NOTE 7 – INCOME TAXES

     

    As of January 1, 2025, the Company had no unrecognized tax benefits, and there has been no change in unrecognized tax benefits during the three months ended March 31, 2025. Accordingly, there was no accrual for uncertain tax positions as of March 31, 2025, and the Company recorded no associated interest or penalties. The Company does not expect any significant changes to this position over the next twelve months.

     

    As of March 31, 2025, the Company and its U.S. subsidiaries remain open to examination by the IRS for years 2021 onwards under the statute of limitations. The Company’s subsidiaries in foreign tax jurisdictions are open to examination including Brazil (2020 onwards), Germany (2020 onwards), and the U.K. (2023 onwards).

    NOTE 8 – LONG-TERM DEBT

    As at March 31, 2025, and December 31, 2024, the Company had not drawn down on its revolving credit facility. During the first three months of 2025 and 2024, the Company did not draw down or repay any borrowing on its revolving credit facility.

    The Company continues to have available a $250.0 million multicurrency revolving credit facility until May 30, 2028.

    As at March 31, 2025, the deferred finance costs of $1.0 million (December 31, 2024 - $1.1 million) related to the arrangement of the revolving credit facility, are included within other current and non-current assets at the balance sheet dates.

    NOTE 9 – PLANT CLOSURE PROVISIONS

    The Company has continuing plans to remediate manufacturing facilities at sites around the world as and when those operations are expected to cease, or we are required to decommission the sites according to local laws and regulations. The liability for estimated plant closure costs includes costs for environmental remediation liabilities and asset retirement obligations.

    The principal site giving rise to asset retirement obligations is the manufacturing site at Ellesmere Port in the U.K.. There are also asset retirement obligations and environmental remediation liabilities on a much smaller scale in respect of other manufacturing sites.

     

    Movements in the provisions are summarized as follows:

     

    (in millions)

     

    2025

     

    Total at January 1

     

    $

    60.3

     

    Charge for the period

     

     

    0.8

     

    Utilized in the period

     

     

    (1.2

    )

    Exchange effect

     

     

    2.3

     

    Total at March 31

     

     

    62.2

     

    Due within one year

     

     

    (5.0

    )

    Due after one year

     

    $

    57.2

     

     

    The charge for the three months ended March 31, 2025, was $0.8 million (three months ended March 31, 2024 – $0.8 million). The current year charge represents the accounting accretion only, with no changes for the expected cost and scope of future remediation activities. Amounts due within one year refer to provisions where expenditure is expected to arise within one year of the balance sheet date.

    11


     

    NOTE 10 – FAIR VALUE MEASUREMENTS

    The following table presents the carrying amount and fair values of the Company’s financial assets and liabilities measured on a recurring basis:

     

     

    March 31, 2025

     

     

    December 31, 2024

     

    (in millions)

     

    Carrying
    Amount

     

     

    Fair
    Value

     

     

    Carrying
    Amount

     

     

    Fair
    Value

     

    Assets

     

     

     

     

     

     

     

     

     

     

     

     

    Derivatives (Level 1 measurement):

     

     

     

     

     

     

     

     

     

     

     

     

    Other current and non-current assets:

     

     

     

     

     

     

     

     

     

     

     

     

    Emissions Trading Scheme credits

     

     

    4.7

     

     

     

    4.7

     

     

     

    3.9

     

     

     

    3.9

     

    Foreign currency forward exchange contracts

     

     

    1.0

     

     

     

    1.0

     

     

     

    1.5

     

     

     

    1.5

     

    Liabilities

     

     

     

     

     

     

     

     

     

     

     

     

    Non-financial liabilities (Level 3 measurement):

     

     

     

     

     

     

     

     

     

     

     

     

    Acquisition-related contingent consideration

     

     

    22.6

     

     

     

    22.6

     

     

     

    20.1

     

     

     

    20.1

     

     

    The following methods and assumptions were used to estimate the fair values:

    Emissions Trading Scheme credits: The fair value is determined by the open market pricing at the end of the reporting period.

    Foreign currency forward exchange contracts: The fair value of derivatives relating to foreign currency forward exchange contracts are derived from current settlement prices and comparable contracts using current assumptions. Foreign currency forward exchange contracts primarily relate to contracts entered into to hedge future known transactions or hedge balance sheet net cash positions. The movements in the carrying amounts and fair values of these contracts are largely due to changes in exchange rates against the U.S. dollar.

    Acquisition-related contingent consideration: Contingent consideration payable in cash is discounted to its fair value at each balance sheet date. Where contingent consideration is dependent upon pre-determined financial targets, an estimate of the fair value of the likely consideration payable is made at each balance sheet date. The contingent consideration payable has been calculated based on the latest forecast.

    NOTE 11 – DERIVATIVE INSTRUMENTS AND RISK MANAGEMENT

    The Company enters into various foreign currency forward exchange contracts to minimize currency exchange rate exposure from expected future cash flows. As at March 31, 2025, the contracts have maturity dates of up to two years at the date of inception. These foreign currency forward exchange contracts have not been designated as hedging instruments, and their impact on the income statement for the first three months of 2025 was a loss of $2.3 million (first three months of 2024 – a gain of $1.0 million). The gain or loss has been recorded in other income or expense.

    12


     

    NOTE 12 – CONTINGENCIES

    Legal matters

    We are involved from time to time in claims and legal proceedings that result from, and are incidental to, the conduct of our business including business and commercial litigation, and employee and product liability claims.

    As reported in our 2023 Form 10-K, we have incurred financial losses and lodged a civil and criminal legal claim related to a misappropriation of inventory in Brazil. As at the time of filing, there have been no significant developments to report in relation to the claims being made. Consistent with prior quarters, a corresponding asset for the potential legal or insurance recoveries has not been recorded for the resulting financial losses arising from this matter.

    In addition, unrelated to the Brazil matter, in the unlikely event there are an unexpectedly large number of individual claims or proceedings with an adverse resolution, this could in the aggregate have a material adverse effect on the results of operations for a particular year or quarter.

    Guarantees

    The Company and certain of the Company’s consolidated subsidiaries are contingently liable for certain obligations of affiliated companies primarily in the form of guarantees of debt and performance under contracts entered into as a normal business practice. This includes guarantees of non-U.S. excise taxes and customs duties. As at March 31, 2025, such guarantees which are not recognized as liabilities in the condensed consolidated financial statements amounted to $7.8 million (December 31, 2024 - $6.8 million). The remaining terms of the fixed maturity guarantees are up to 8 years, with some further guarantees having no fixed expiry date.

    Under the terms of the guarantee arrangements, generally the Company would be required to perform the obligations should the affiliated company fail to fulfill its obligations under the arrangements. In some cases, the guarantee arrangements have recourse provisions that would enable the Company to recover any payments made under the terms of the guarantees from securities held of the guaranteed parties’ assets.

    The Company and its affiliates have numerous long-term sales and purchase commitments in their various business activities, which are expected to be fulfilled with no adverse consequences material to the Company.

    13


     

    NOTE 13 – STOCK-BASED COMPENSATION PLANS

    The compensation cost recorded for stock options for the three months ended March 31, 2025 and 2024 was $1.9 million and $2.1 million, respectively.

    The compensation cost recorded for stock equivalent units for the three months ended March 31, 2025 and 2024 was $0.2 million and $2.5 million, respectively.

    The following table summarizes the transactions of the Company’s share-based compensation plans for the three months ended March 31, 2025.

     

     

    Number of
    shares

     

     

    Weighted
    Average
    Grant-Date
    Fair Value

     

    Nonvested at December 31, 2024

     

     

    574,671

     

     

    $

    86.2

     

    Granted

     

     

    166,037

     

     

    $

    105.2

     

    Vested

     

     

    (151,347

    )

     

    $

    87.3

     

    Forfeited

     

     

    (8,087

    )

     

    $

    74.0

     

    Nonvested at March 31, 2025

     

     

    581,274

     

     

    $

    91.3

     

     

    For the awards granted with market conditions, a Monte Carlo model has been used to calculate the grant-date fair value. For all other awards granted, a fair market value methodology has been used to calculate the grant-date fair value.

    The awards granted with market conditions include a performance measure for Innospec's total shareholder return as compared to a peer group of companies. This measure can result in a maximum 130% vesting for the number of stock options granted. The maximum potential vesting has been reflected in the grant-date fair value calculation, but not reflected for the number of awards granted, as shown in the table above. All other awards granted in the quarter have similar vesting conditions to those granted in the previous periods.

    As of March 31, 2025, there was $31.0 million of total unrecognized compensation cost related to nonvested share-based compensation arrangements. That cost is expected to be recognized over a weighted-average period of 2.3 years.

    NOTE 14 – RECLASSIFICATIONS OUT OF ACCUMULATED OTHER COMPREHENSIVE LOSS

    Reclassifications out of accumulated other comprehensive loss (“AOCL”) for the first three months of 2025 were:

     

    (in millions)
    Details about AOCL Components

     

    Amount
    Reclassified
    from AOCL

     

     

    Affected Line Item in the
    Statement where
    Net Income is Presented

    Defined benefit pension plan items:

     

     

     

     

     

    Amortization of prior service cost

     

    $

    —

     

     

    See (1) below

    Amortization of actuarial net gains

     

     

    —

     

     

    See (1) below

     

     

    —

     

     

    Total before tax

     

     

    —

     

     

    Income tax expense

    Total reclassifications

     

    $

    —

     

     

    Net of tax

     

    (1)
    These items are included in other income and expense. See Note 6 of the Notes to the Condensed Consolidated Financial Statements for additional information.

     

    14


     

    Changes in AOCL for the first three months of 2025, net of tax, were:

     

    (in millions)

     

    Defined
    Benefit
    Pension
    Plan Items

     

     

    Cumulative
    Translation
    Adjustments

     

     

    Total

     

    Balance at December 31, 2024

     

    $

    —

     

     

    $

    (91.0

    )

     

    $

    (91.0

    )

    Other comprehensive income/(loss) before reclassifications

     

     

    —

     

     

     

    18.7

     

     

     

    18.7

     

    Amounts reclassified from AOCL

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Total other comprehensive income/(loss)

     

     

    —

     

     

     

    18.7

     

     

     

    18.7

     

    Balance at March 31, 2025

     

    $

    —

     

     

    $

    (72.3

    )

     

    $

    (72.3

    )

     

     

    Reclassifications out of AOCL for the first three months of 2024 were:

     

    (in millions)
    Details about AOCL Components

     

    Amount
    Reclassified
    from AOCL

     

     

    Affected Line Item in the
    Statement where
    Net Income is Presented

    Defined benefit pension plan items:

     

     

     

     

     

    Amortization of prior service cost

     

    $

    0.1

     

     

    See (1) below

    Amortization of actuarial net gains

     

     

    (0.1

    )

     

    See (1) below

     

     

    —

     

     

    Total before tax

     

     

    —

     

     

    Income tax expense

    Total reclassifications

     

    $

    —

     

     

    Net of tax

     

    (1)
    These items are included in other income and expense. See Note 6 of the Notes to the Condensed Consolidated Financial Statements for additional information.

    Changes in AOCL for the first three months of 2024, net of tax, were:

     

    (in millions)

     

    Defined
    Benefit
    Pension
    Plan Items

     

     

    Cumulative
    Translation
    Adjustments

     

     

    Total

     

    Balance at December 31, 2023

     

    $

    (77.2

    )

     

    $

    (70.9

    )

     

    $

    (148.1

    )

    Other comprehensive income/(loss) before reclassifications

     

     

    —

     

     

     

    (7.3

    )

     

     

    (7.3

    )

    Amounts reclassified from AOCL

     

     

    —

     

     

     

    —

     

     

     

    —

     

    Total other comprehensive income/(loss)

     

     

    —

     

     

     

    (7.3

    )

     

     

    (7.3

    )

    Balance at March 31, 2024

     

    $

    (77.2

    )

     

    $

    (78.2

    )

     

    $

    (155.4

    )

     

    NOTE 15 – RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

     

    The Company has reviewed recently issued accounting pronouncements and concluded there were no matters relevant to the Company’s financial statements.

     

    15


     

    NOTE 16 – RELATED PARTY TRANSACTIONS

    Mr. Patrick S. Williams has been an executive director of the Company since April 2009 and has been a non-executive director of AdvanSix Inc. ("AdvanSix"), a chemicals manufacturer, since February 2020. In the first three months of 2025 the Company did not purchase any product from AdvanSix (first three months of 2024 – nil). As at March 31, 2025, the Company owed nil to AdvanSix (December 31, 2024 – nil).

    Mr. Robert I. Paller was a non-executive director of the Company since November 1, 2009 until May 10, 2024, when he did not stand for re-election to the board. The Company has engaged the services of Smith, Gambrell & Russell, LLP (“SGR”), a law firm with which Mr. Paller held a position. In the first three months of 2024 the Company incurred fees from SGR of $0.2 million.

    Mr. David F. Landless has been a non-executive director of the Company since January 1, 2016 and is a non-executive director of Ausurus Group Limited which owns European Metal Recycling Limited (“EMR”) which from time to time purchases scrap metal from the Company. The Company has sold no scrap metal to EMR in the first three months of 2025 (first three months of 2024 – less than $0.1 million). A tendering process is operated periodically to select the best buyer for the sale of scrap metal by the Company. As at March 31, 2025, EMR owed nil for scrap metal purchased from the Company (December 31, 2024 – nil).

     

    16


     

    Item 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three Months Ended March 31, 2025

    This discussion should be read in conjunction with our unaudited interim condensed consolidated financial statements and the notes thereto.

    CRITICAL ACCOUNTING ESTIMATES

    The policies and estimates that the Company considers the most critical in terms of complexity and subjectivity of assessment are those related to plant closure provisions, income taxes and goodwill. These policies have been discussed in the Company’s 2024 Form 10-K.

    RESULTS OF OPERATIONS

    The Company reports its financial performance based on three reportable segments, which are Performance Chemicals, Fuel Specialties and Oilfield Services.

    The following table provides sales, gross profit and operating income by reporting segment:

     

     

    Three Months Ended
    March 31,

     

    (in millions)

     

    2025

     

     

    2024

     

    Net sales:

     

     

     

     

     

     

    Performance Chemicals

     

    $

    168.4

     

     

    $

    160.8

     

    Fuel Specialties

     

     

    170.3

     

     

     

    176.9

     

    Oilfield Services

     

     

    102.1

     

     

     

    162.5

     

     

    $

    440.8

     

     

    $

    500.2

     

    Gross profit:

     

     

     

     

     

     

    Performance Chemicals

     

    $

    35.3

     

     

    $

    37.7

     

    Fuel Specialties

     

     

    60.8

     

     

     

    60.6

     

    Oilfield Services

     

     

    29.0

     

     

     

    57.4

     

     

    $

    125.1

     

     

    $

    155.7

     

    Operating income/(loss):

     

     

     

     

     

     

    Performance Chemicals

     

    $

    19.8

     

     

    $

    21.1

     

    Fuel Specialties

     

     

    36.9

     

     

     

    33.4

     

    Oilfield Services

     

     

    4.1

     

     

     

    16.9

     

    Corporate costs

     

     

    (17.7

    )

     

     

    (20.2

    )

    Adjustment to fair value of contingent consideration

     

     

    (0.7

    )

     

     

    (0.8

    )

    Profit on disposal of property, plant and equipment

     

     

    0.1

     

     

     

    0.1

     

    Total operating income

     

    $

    42.5

     

     

    $

    50.5

     

     

    17


     

    Three Months Ended March 31, 2025

    The following table shows the changes in sales, gross profit and operating expenses by reporting segment for the three months ended March 31, 2025, and the three months ended March 31, 2024:

     

     

    Three Months Ended
    March 31,

     

     

     

     

     

     

    (in millions, except ratios)

     

    2025

     

     

    2024

     

     

    Change

     

     

     

    Net sales:

     

     

     

     

     

     

     

     

     

     

     

    Performance Chemicals

     

    $

    168.4

     

     

    $

    160.8

     

     

    $

    7.6

     

     

    +5%

    Fuel Specialties

     

     

    170.3

     

     

     

    176.9

     

     

     

    (6.6

    )

     

    -4%

    Oilfield Services

     

     

    102.1

     

     

     

    162.5

     

     

     

    (60.4

    )

     

    -37%

     

    $

    440.8

     

     

    $

    500.2

     

     

    $

    (59.4

    )

     

    -12%

    Gross profit:

     

     

     

     

     

     

     

     

     

     

     

    Performance Chemicals

     

    $

    35.3

     

     

    $

    37.7

     

     

    $

    (2.4

    )

     

    -6%

    Fuel Specialties

     

     

    60.8

     

     

     

    60.6

     

     

     

    0.2

     

     

    +0%

    Oilfield Services

     

     

    29.0

     

     

     

    57.4

     

     

     

    (28.4

    )

     

    -49%

     

    $

    125.1

     

     

    $

    155.7

     

     

    $

    (30.6

    )

     

    -20%

    Gross margin (%):

     

     

     

     

     

     

     

     

     

     

     

    Performance Chemicals

     

     

    21.0

     

     

     

    23.4

     

     

     

    -2.4

     

     

     

    Fuel Specialties

     

     

    35.7

     

     

     

    34.3

     

     

     

    +1.4

     

     

     

    Oilfield Services

     

     

    28.4

     

     

     

    35.3

     

     

     

    -6.9

     

     

     

    Aggregate

     

     

    28.4

     

     

     

    31.1

     

     

     

    -2.7

     

     

     

    Operating expenses:

     

     

     

     

     

     

     

     

     

     

     

    Performance Chemicals

     

    $

    (15.5

    )

     

    $

    (16.6

    )

     

    $

    1.1

     

     

    -7%

    Fuel Specialties

     

     

    (23.9

    )

     

     

    (27.2

    )

     

     

    3.3

     

     

    -12%

    Oilfield Services

     

     

    (24.9

    )

     

     

    (40.5

    )

     

     

    15.6

     

     

    -39%

    Corporate costs

     

     

    (17.7

    )

     

     

    (20.2

    )

     

     

    2.5

     

     

    -12%

    Adjustment to fair value of contingent consideration

     

     

    (0.7

    )

     

     

    (0.8

    )

     

     

    0.1

     

     

    -13%

    Profit on disposal of property, plant and equipment

     

     

    0.1

     

     

     

    0.1

     

     

     

    —

     

     

    n/a

     

    $

    (82.6

    )

     

    $

    (105.2

    )

     

    $

    22.6

     

     

    -21%

     

    Performance Chemicals

    Net sales: the table below details the components which comprise the year over year change in net sales spread across the markets in which we operate:

     

     

    Three Months Ended March 31, 2025

     

    Change (%)

     

    Americas

     

     

    EMEA

     

     

    ASPAC

     

     

    Total

     

    Volume

     

     

    +11

     

     

     

    -3

     

     

     

    +31

     

     

     

    +5

     

    Price and product mix

     

     

    -6

     

     

     

    +9

     

     

     

    +8

     

     

     

    +3

     

    Exchange rates

     

     

    —

     

     

     

    -5

     

     

     

    -3

     

     

     

    -3

     

     

     

    +5

     

     

     

    +1

     

     

     

    +36

     

     

     

    +5

     

     

    Higher sales volumes for the Americas were driven by increased demand for our personal care products, being partly offset by an adverse price and product mix due to higher demand for our lower priced products. The volumes decline in EMEA was offset by a favorable price and product mix, primarily driven by higher demand for higher priced personal care products. ASPAC volumes were higher driven by increased demand for our personal care products, together with a favorable price and product mix due to higher demand for higher priced personal care products. EMEA and ASPAC were adversely affected by foreign currency exchange rate movements.

    Gross margin: the year over year decrease of 2.4 percentage points was primarily due to pricing pressure in a competitive market being partly driven by the recent global economic uncertainty and higher demand for our lower priced products.

    18


     

    Operating expenses: decreased by $1.1 million year over year due to lower provisions for doubtful debts, together with lower provisions for bonuses and performance-related remuneration accruals.

    Fuel Specialties

    Net sales: the table below details the components which comprise the year over year change in net sales spread across the markets in which we operate:

     

     

    Three Months Ended March 31, 2025

     

    Change (%)

     

    Americas

     

     

    EMEA

     

     

    ASPAC

     

     

    AvGas

     

     

    Total

     

    Volume

     

     

    +1

     

     

     

    +3

     

     

     

    -16

     

     

     

    +17

     

     

     

    —

     

    Price and product mix

     

     

    -3

     

     

     

    -3

     

     

     

    +3

     

     

     

    +9

     

     

     

    -2

     

    Exchange rates

     

     

    —

     

     

     

    -5

     

     

     

    -1

     

     

     

    —

     

     

     

    -2

     

     

     

    -2

     

     

     

    -5

     

     

     

    -14

     

     

     

    +26

     

     

     

    -4

     

     

    Sales volumes in the Americas and EMEA have increased year over year due to increased demand from customers, being offset by an adverse price and product mix from lower pricing resulting from lower raw material costs. Sales volumes in ASPAC have decreased year over year due to decreased demand from customers, being partly offset by a favorable price and product mix due to an improved sales mix. AvGas volumes were higher than the prior year due to variations in the demand from customers, together with a favorable price and product mix due to a favorable customer mix. EMEA and ASPAC were adversely affected by foreign currency exchange rate movements.

    Gross margin: the year over year increase of 1.4 percentage points was driven by an improved sales mix from increased sales of higher margin products, together with reduced raw material and other inflationary pressures.

    Operating expenses: the year over year decrease of $3.3 million was due to lower provisions for doubtful debts, together with lower provisions for bonuses and performance-related remuneration accruals.

    Oilfield Services

    Net sales: have decreased year over year by $60.4 million, or 37 percent, with the majority of our customer activity concentrated in the Americas region. Sales volumes were adversely impacted by significantly lower production chemical activity in Latin America. Management continues to see potential growth opportunities for our other oilfield markets.

    Gross margin: the year over year decrease of 6.9 percentage points was due to an unfavorable sales mix as our customer demand has weakened.

    Operating expenses: the year over year decrease of $15.6 million was due to lower customer service costs and commissions related to the reduced demand from certain customers, together with lower provisions for bonuses and performance-related remuneration accruals.

    Other Income Statement Captions

    Corporate costs: the year over year decrease of $2.5 million was primarily due to lower provisions for bonuses and performance-related remuneration accruals, being partly offset by the additional investment in our IT infrastructure and the amortization of our new group-wide ERP system.

    19


     

    Other net income/(expense): for the first quarter of 2025 and 2024, included the following:

     

    (in millions)

     

    2025

     

     

    2024

     

     

    Change

     

    Net pension credit

     

    $

    (0.1

    )

     

    $

    1.7

     

     

    $

    (1.8

    )

    Profit attributable to non-controlling interests

     

     

    (0.8

    )

     

     

    (0.1

    )

     

     

    (0.7

    )

    Foreign exchange gains/(losses) on translation

     

     

    2.7

     

     

     

    0.1

     

     

     

    2.6

     

    Foreign currency forward contracts gains/(losses)

     

     

    (2.3

    )

     

     

    1.0

     

     

     

    (3.3

    )

     

    $

    (0.5

    )

     

    $

    2.7

     

     

    $

    (3.2

    )

     

    Interest income/(expense), net: in the first quarter of 2025 was $2.4 million of income compared to $2.1 million of income in the first quarter of 2024, driven by the interest income being earned from our higher cash balances.

     

    Income taxes: the effective tax rate was 26.1% and 25.1% in the first quarter of 2025 and 2024, respectively. The adjusted effective tax rate, once adjusted for the items set out in the following table, was 24.4% in 2025 compared with 24.5% in 2024. The 0.1% decrease in the adjusted effective rate was primarily due to the fact that a higher proportion of the Company’s profits are being generated in lower tax jurisdictions. The Company believes that this adjusted effective tax rate, a non-GAAP financial measure, provides useful information to investors and may assist them in evaluating the Company’s underlying performance and identifying operating trends. In addition, management uses this non-GAAP financial measure internally to evaluate the performance of the Company’s operations and for planning and forecasting in subsequent periods.

    The following table shows a reconciliation of the GAAP effective tax charge to the adjusted effective tax charge:

     

     

    Three Months Ended
    March 31,

     

    (in millions)

     

    2025

     

     

    2024

     

    Income before income taxes

     

    $

    44.4

     

     

    $

    55.3

     

    Indemnification asset regarding tax audit

     

     

    —

     

     

     

    0.1

     

    Adjustment for stock compensation

     

     

    2.0

     

     

     

    2.1

     

    Adjustment to fair value of contingent consideration

     

     

    0.7

     

     

     

    0.8

     

    Legacy costs of closed operations

     

     

    0.8

     

     

     

    0.8

     

    Adjusted income before income taxes

     

    $

    47.9

     

     

    $

    59.1

     

    Income taxes

     

    $

    11.6

     

     

    $

    13.9

     

    Tax on stock compensation

     

     

    (0.1

    )

     

     

    (0.1

    )

    Adjustment of income tax provision

     

     

    —

     

     

     

    0.2

     

    Tax on adjustment to fair value of contingent consideration

     

     

    —

     

     

     

    0.3

     

    Tax on legacy cost of closed operations

     

     

    0.2

     

     

     

    0.2

     

    Adjusted income taxes

     

    $

    11.7

     

     

    $

    14.5

     

    GAAP effective tax rate

     

     

    26.1

    %

     

     

    25.1

    %

    Adjusted effective tax rate

     

     

    24.4

    %

     

     

    24.5

    %

     

     

    20


     

    LIQUIDITY AND FINANCIAL CONDITION

    Working Capital

    In the first three months of 2025 our working capital increased by $34.3 million, while our adjusted working capital increased by $27.1 million. The difference is primarily due to the exclusion of the increases for cash and cash equivalents, together with the changes for the current portion of income taxes.

    The Company believes that adjusted working capital, a non-GAAP financial measure (defined by the Company as trade and other accounts receivable, inventories, prepaid expenses, accounts payable and accrued liabilities rather than total current assets less total current liabilities) provides useful information to investors in evaluating the Company’s underlying performance and identifying operating trends. Management uses this non-GAAP financial measure internally to allocate resources and evaluate the performance of the Company’s operations. Items excluded from working capital in the adjusted working capital calculation are listed in the table below and represent factors which do not fluctuate in line with the day to day working capital needs of the business.

     

    (in millions)

     

    March 31,
    2025

     

     

    December 31,
    2024

     

    Total current assets

     

    $

    977.1

     

     

    $

    956.6

     

    Total current liabilities

     

     

    (357.6

    )

     

     

    (371.4

    )

    Working capital

     

     

    619.5

     

     

     

    585.2

     

    Less cash and cash equivalents

     

     

    (299.8

    )

     

     

    (289.2

    )

    Less prepaid income taxes

     

     

    (1.0

    )

     

     

    (3.1

    )

    Less other current assets

     

     

    (1.4

    )

     

     

    (0.6

    )

    Add back accrued income taxes

     

     

    21.6

     

     

     

    19.6

     

    Add back current portion of plant closure provisions

     

     

    5.0

     

     

     

    5.0

     

    Add back current portion of operating lease liabilities

     

     

    14.0

     

     

     

    13.9

     

    Adjusted working capital

     

    $

    357.9

     

     

    $

    330.8

     

     

    We had a $1.8 million increase in trade and other accounts receivable due to the timing of cash collections and sales in each of our segments. Days’ sales outstanding increased in our Performance Chemicals segment from 61 days to 63 days; increased from 57 days to 60 days in our Fuel Specialties segment; and decreased from 83 days to 75 days in our Oilfield Services segment.

    We had a $14.4 million increase in inventories, including a $1.2 million increase in allowances, driven by higher levels of finished goods due to higher production in advance of planned maintenance shutdowns. The Company continues to maintain inventory levels necessary to manage the risk of potential supply chain disruption for certain key raw materials, especially in our Fuel Specialties segment. Days’ sales in inventory in our Performance Chemicals segment increased from 63 days to 67 days; increased from 113 days to 129 days in our Fuel Specialties segment; and decreased from 76 days to 67 days in our Oilfield Services segment.

    Prepaid expenses decreased $5.0 million, from $21.0 million to $16.0 million, primarily due to the normal expensing of prepaid invoices.

    We had a $15.9 million decrease in accounts payable and accrued liabilities, which was dependent on the timing of payments for each of our reporting segments. Creditor days (including goods received not invoiced) have increased in our Performance Chemicals segment from 46 days to 47 days; increased from 44 days to 54 days in our Fuel Specialties segment; and decreased from 68 days to 59 days in our Oilfield Services segment. The changes for creditor days have been impacted by the timing of sales and cost of sales in the quarter, when using a countback methodology.

     

    21


     

    Operating Cash Flows

    We generated cash from operating activities of $28.3 million in the first three months of 2025 compared to $80.6 million in the first three months of 2024. The decrease in cash generated from operating activities was related to decreased operating income and less favorable working capital cash flows primarily related to the increased inventory levels needed to secure the supply of certain raw materials.

    Cash

    At March 31, 2025 and December 31, 2024, we had cash and cash equivalents of $299.8 million and $289.2 million, respectively, of which $143.9 million and $133.9 million, respectively, were held by non-U.S. subsidiaries principally in the United Kingdom.

    The increase in cash and cash equivalents of $10.6 million for the first three months of 2025 was primarily driven by our positive trading cash flow, being partly offset by our continued investments in capital projects and our repurchases of common stock.

    Debt

    We continue to have available a $250.0 million multicurrency revolving credit facility.

    At March 31, 2025, and December 31, 2024, we had no debt outstanding under the revolving credit facility and no obligations were outstanding under finance leases. See Note 8 of the Notes to the Condensed Consolidated Financial Statements for additional information.

     

    22


     

    Item 3 Quantitative and Qualitative Disclosures about Market Risk

    The Company uses floating rate debt to finance its global operations. The Company is subject to business risks inherent in non-U.S. activities, including political and economic uncertainty, import and export limitations, and market risk related to changes in interest rates and foreign currency exchange rates. The political and economic risks are mitigated by the stability of the major countries in which the Company’s largest operations are located. Credit limits, ongoing credit evaluation and account monitoring procedures are used to minimize bad debt risk. Collateral is not generally required.

    From time to time, the Company uses derivatives, including interest rate swaps, commodity swaps and foreign currency forward exchange contracts, in the normal course of business to manage market risks. The derivatives used in hedging activities are considered risk management tools and are not used for trading purposes. In addition, the Company enters into derivative instruments with a diversified group of major financial institutions in order to manage the exposure to non-performance of such instruments. The Company’s objective in managing the exposure to changes in interest rates is to limit the impact of such changes on earnings and cash flows and to lower overall borrowing costs. The Company’s objective in managing the exposure to changes in foreign currency exchange rates is to reduce volatility on earnings and cash flows associated with such changes.

    The Company offers fixed prices for some long-term sales contracts. As manufacturing and raw material costs are subject to variability, the Company, from time to time, uses commodity swaps to hedge the cost of some raw materials thus reducing volatility on earnings and cash flows. The derivatives are considered risk management tools and are not used for trading purposes. The Company’s objective is to manage its exposure to fluctuating costs of raw materials.

    The Company’s exposure to market risk has been discussed in the 2024 Form 10-K and there have been no significant changes since that time.

    23


     

    Item 4 Controls and Procedures

    Evaluation of Disclosure Controls and Procedures

    Based on an evaluation carried out as of the end of the period covered by this report, under the supervision and with the participation of our management, our Chief Executive Officer and our Chief Financial Officer concluded that the Company’s “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) were effective as of March 31, 2025, to provide reasonable assurance that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and (ii) accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

    Changes in Internal Control over Financial Reporting

    The Company is continuously seeking to improve the efficiency and effectiveness of its operations and of its internal control over financial reporting. This is intended to result in refinements to processes throughout the Company.

    As previously disclosed, we are continuing with the development of a new, company-wide, information system platform which began in 2022. The new platform provider is well established in the market. The implementation is a phased, risk-managed, site deployment following a multistage user acceptance program with the existing platform providing a fallback position. In connection with this implementation, the Company has updated its internal controls over financial reporting, as necessary, to accommodate modifications to its business processes and accounting procedures.

    There were no changes to our internal control over financial reporting which were identified in connection with the evaluation required by paragraph (d) of Rules 13a-15 and 15d-15 under the Securities Exchange Act of 1934, that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

    24


     

    PART II OTHER INFORMATION

    Item 1 Legal Proceedings

    Legal matters

    We are involved from time to time in claims and legal proceedings that result from, and are incidental to, the conduct of our business including business and commercial litigation, employee and product liability claims.

    As reported in our 2023 Form 10-K, we have incurred financial losses and lodged a civil and criminal legal claim related to a misappropriation of inventory in Brazil. As at the time of filing, there have been no significant developments to report in relation to the claims being made. Consistent with prior quarters, a corresponding asset for the potential legal or insurance recoveries has not been recorded for the resulting financial losses arising from this matter.

    In addition, unrelated to the Brazil matter, in the unlikely event there are an unexpectedly large number of individual claims or proceedings with an adverse resolution, this could in the aggregate have a material adverse effect on the results of operations for a particular year or quarter.

    Item 1A Risk Factors

    Information regarding risk factors that could have a material impact on our results of operations or financial condition are described under “Risk Factors” in Item 1A of Part I of our 2024 Form 10-K. In management’s view, there have been no material changes in the risk factors facing the Company as disclosed in those SEC filings.

    Item 2 Unregistered Sales of Equity Securities and Use of Proceeds

    There have been no unregistered sales of equity securities.

     

    On March 10, 2025, the Company announced a repurchase program which allows for up to $50 million of the Company’s common stock to be repurchased in the open market over a three-year period commencing on March 10, 2025. The previous repurchase program ended in February 2025. The company also repurchases its common stock in connection with the exercising of stock options by directors and employees. The following table provides information about our repurchases of equity securities in the period.

     

    Period

     

    Total number
    of shares
    purchased

     

     

    Average price
    paid per share

     

     

    Total number of
    shares purchased
    as part of publicly
    announced plans or
    programs

     

     

    Approximate dollar
    value of shares that
    may yet be purchased
    under the plans or
    programs

    February 1, 2025 through February 28, 2025

     

     

    1,227

     

     

    $

    105.1

     

     

     

    —

     

     

    $

    50.0

     

    million

    March 1, 2025 through March 31, 2025

     

     

    46,823

     

     

    $

    99.0

     

     

     

    34,100

     

     

    $

    46.7

     

    million

    Total

     

     

    48,050

     

     

    $

    99.1

     

     

     

    34,100

     

     

    $

    46.7

     

    million

    Item 3 Defaults Upon Senior Securities

    None.

    Item 4 Mine Safety Disclosures

    Not applicable.

    Item 5 Other Information

    (a), (b), and (c) – None.

    25


     

    Item 6 Exhibits

     

     

    31.1

     

    Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

    31.2

     

    Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

    32.1

     

    Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

    32.2

     

    Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

    101

     

    XBRL Instance Document and Related Item - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the inline XBRL document.

    104

     

    Cover Page Interactive Data File – The cover page XBRL tags are embedded within the inline XBRL document.

     

    26


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

     

     

    INNOSPEC INC.

     

    Registrant

     

     

     

     

    Date: May 9, 2025

    By

     

     /s/ PATRICK S. WILLIAMS

     

     

     

    Patrick S. Williams

    President and Chief Executive Officer

     

     

     

     

    Date: May 9, 2025

    By

     

    /s/ IAN P. CLEMINSON

     

     

     

    Ian P. Cleminson

    Executive Vice President and Chief Financial Officer

     

    27


    Get the next $IOSP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IOSP

    DatePrice TargetRatingAnalyst
    4/21/2025$115.00Neutral → Buy
    Seaport Research Partners
    3/30/2022Neutral
    Seaport Research Partners
    More analyst ratings

    $IOSP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Innospec Reports First Quarter 2025 Financial Results

      Balanced results considering market volatility Excellent growth in Fuels Specialties offsetting lower results in Performance Chemicals and Oilfield Services $28.3 million cash generated from operations; Net cash improves to $299.8 million Dividend increased by 10 percent; $50 million buyback initiated; Flexible debt-free balance sheet GAAP EPS of $1.31 and adjusted non-GAAP EPS of $1.42 ENGLEWOOD, Colo., May 08, 2025 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ:IOSP) today announced its financial results for the first quarter ended March 31, 2025. The Company declared its semi-annual dividend of 84 cents per common share for the first half of this year, representing an increase of 10 per

      5/8/25 4:45:00 PM ET
      $IOSP
      Major Chemicals
      Industrials
    • Innospec Schedules First Quarter 2025 Earnings Release and Conference Call

      ENGLEWOOD, Colo., April 03, 2025 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ:IOSP) today announced that it will release first quarter 2025 earnings results on Thursday, May 8, 2025 after market close. Following the release of its results, Patrick S. Williams, President and Chief Executive Officer, and Ian Cleminson, Executive Vice President and Chief Financial Officer, will host an interactive conference call on Friday, May 9, 2025, at 9:00 a.m. ET. The public is invited to listen to the conference call by registering in advance using the below Online Registration Link. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique Personal PIN which

      4/3/25 5:45:00 PM ET
      $IOSP
      Major Chemicals
      Industrials
    • Innospec Approves New $50MM Share Repurchase Program

      ENGLEWOOD, Colo., March 10, 2025 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ:IOSP) today announces that its Board of Directors has approved a new $50 million share repurchase program. The company's prior $50 million share repurchase program expired in the first quarter of 2025. Patrick S. Williams, President and Chief Executive Officer, said, "With over $289 million in net cash, we continue to have significant flexibility and balance sheet strength for further M&A, organic investment, dividend growth and share repurchases under this renewed buyback program." Purchases may be made from time to time at management's discretion. About Innospec Inc. Innospec Inc. is an international special

      3/10/25 4:45:00 PM ET
      $IOSP
      Major Chemicals
      Industrials

    $IOSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $IOSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $IOSP
    SEC Filings

    See more

    $IOSP
    Financials

    Live finance-specific insights

    See more

    $IOSP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Innospec upgraded by Seaport Research Partners with a new price target

      Seaport Research Partners upgraded Innospec from Neutral to Buy and set a new price target of $115.00

      4/21/25 8:30:53 AM ET
      $IOSP
      Major Chemicals
      Industrials
    • Seaport Research Partners initiated coverage on Innospec

      Seaport Research Partners initiated coverage of Innospec with a rating of Neutral

      3/30/22 7:37:48 AM ET
      $IOSP
      Major Chemicals
      Industrials
    • PRESIDENT & CEO Williams Patrick covered exercise/tax liability with 12,723 shares, decreasing direct ownership by 6% to 199,689 units (SEC Form 4)

      4 - INNOSPEC INC. (0001054905) (Issuer)

      3/4/25 6:49:24 PM ET
      $IOSP
      Major Chemicals
      Industrials
    • EVP & CFO Cleminson Ian sold $431,679 worth of shares (4,275 units at $100.98), decreasing direct ownership by 21% to 15,858 units (SEC Form 4)

      4 - INNOSPEC INC. (0001054905) (Issuer)

      3/4/25 6:44:58 PM ET
      $IOSP
      Major Chemicals
      Industrials
    • SEC Form 4 filed by Senior VP R&T Mcrobbie Ian Malcolm

      4 - INNOSPEC INC. (0001054905) (Issuer)

      2/27/25 8:58:17 PM ET
      $IOSP
      Major Chemicals
      Industrials
    • SEC Form 10-Q filed by Innospec Inc.

      10-Q - INNOSPEC INC. (0001054905) (Filer)

      5/9/25 9:46:52 AM ET
      $IOSP
      Major Chemicals
      Industrials
    • SEC Form 8-K filed by Innospec Inc.

      8-K - INNOSPEC INC. (0001054905) (Filer)

      5/9/25 6:10:55 AM ET
      $IOSP
      Major Chemicals
      Industrials
    • SEC Form DEFA14A filed by Innospec Inc.

      DEFA14A - INNOSPEC INC. (0001054905) (Filer)

      3/27/25 4:43:13 PM ET
      $IOSP
      Major Chemicals
      Industrials
    • Innospec Reports First Quarter 2025 Financial Results

      Balanced results considering market volatility Excellent growth in Fuels Specialties offsetting lower results in Performance Chemicals and Oilfield Services $28.3 million cash generated from operations; Net cash improves to $299.8 million Dividend increased by 10 percent; $50 million buyback initiated; Flexible debt-free balance sheet GAAP EPS of $1.31 and adjusted non-GAAP EPS of $1.42 ENGLEWOOD, Colo., May 08, 2025 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ:IOSP) today announced its financial results for the first quarter ended March 31, 2025. The Company declared its semi-annual dividend of 84 cents per common share for the first half of this year, representing an increase of 10 per

      5/8/25 4:45:00 PM ET
      $IOSP
      Major Chemicals
      Industrials
    • Innospec Schedules First Quarter 2025 Earnings Release and Conference Call

      ENGLEWOOD, Colo., April 03, 2025 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ:IOSP) today announced that it will release first quarter 2025 earnings results on Thursday, May 8, 2025 after market close. Following the release of its results, Patrick S. Williams, President and Chief Executive Officer, and Ian Cleminson, Executive Vice President and Chief Financial Officer, will host an interactive conference call on Friday, May 9, 2025, at 9:00 a.m. ET. The public is invited to listen to the conference call by registering in advance using the below Online Registration Link. Upon registering, each participant will receive an email confirmation with dial-in numbers and a unique Personal PIN which

      4/3/25 5:45:00 PM ET
      $IOSP
      Major Chemicals
      Industrials
    • Innospec Approves New $50MM Share Repurchase Program

      ENGLEWOOD, Colo., March 10, 2025 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ:IOSP) today announces that its Board of Directors has approved a new $50 million share repurchase program. The company's prior $50 million share repurchase program expired in the first quarter of 2025. Patrick S. Williams, President and Chief Executive Officer, said, "With over $289 million in net cash, we continue to have significant flexibility and balance sheet strength for further M&A, organic investment, dividend growth and share repurchases under this renewed buyback program." Purchases may be made from time to time at management's discretion. About Innospec Inc. Innospec Inc. is an international special

      3/10/25 4:45:00 PM ET
      $IOSP
      Major Chemicals
      Industrials
    • SEC Form SC 13G/A filed by Innospec Inc. (Amendment)

      SC 13G/A - INNOSPEC INC. (0001054905) (Subject)

      2/13/24 5:06:27 PM ET
      $IOSP
      Major Chemicals
      Industrials
    • SEC Form SC 13G/A filed by Innospec Inc. (Amendment)

      SC 13G/A - INNOSPEC INC. (0001054905) (Subject)

      2/9/24 2:18:58 PM ET
      $IOSP
      Major Chemicals
      Industrials
    • SEC Form SC 13G/A filed by Innospec Inc. (Amendment)

      SC 13G/A - INNOSPEC INC. (0001054905) (Subject)

      1/12/24 8:24:55 AM ET
      $IOSP
      Major Chemicals
      Industrials

    $IOSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Parrette Leslie J bought $15,135 worth of shares (143 units at $105.84), increasing direct ownership by 3% to 4,734 units (SEC Form 4)

      4 - INNOSPEC INC. (0001054905) (Issuer)

      8/14/24 6:31:38 PM ET
      $IOSP
      Major Chemicals
      Industrials
    • Parrette Leslie J bought $24,867 worth of shares (189 units at $131.57), increasing direct ownership by 4% to 4,591 units (SEC Form 4)

      4 - INNOSPEC INC. (0001054905) (Issuer)

      5/20/24 6:07:17 PM ET
      $IOSP
      Major Chemicals
      Industrials
    • Parrette Leslie J bought $50,824 worth of shares (410 units at $123.96), increasing direct ownership by 13% to 3,620 units (SEC Form 4)

      4 - INNOSPEC INC. (0001054905) (Issuer)

      2/23/24 6:19:14 PM ET
      $IOSP
      Major Chemicals
      Industrials

    $IOSP
    Leadership Updates

    Live Leadership Updates

    See more
    • Innospec Appoints Leslie J. Parrette as Non-Employee Director

      ENGLEWOOD, Colo., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Innospec Inc. (NASDAQ:IOSP) today announced that it has appointed Mr. Leslie J. Parrette as a non-employee director, effective January 1, 2022. Mr. Parrette has 14 years experience in private practice as a corporate and transaction lawyer. He subsequently spent 20 years as General Counsel for public companies in domestic and international markets. Most recently, he served as Senior Vice President, General Counsel, Compliance Officer and Corporate Secretary of Novelis Inc., a leading producer of flat-rolled aluminum products and the world's largest recycler of aluminum. He is Founder and President of One Page Thinking, a data visualizatio

      12/6/21 4:45:00 PM ET
      $IOSP
      Major Chemicals
      Industrials